Ру O’z Ўзб Eng
+998 71 228-06-96

+998 78 120-16-61

1002
not found
Кенгайтирилган қидирув

    JSC "Dori - Darmon" -
    we are trusted by all generations!

    not found

    Our mission is safe and affordable medicines

    not found
    not found
    not found
    not found

    Interactive Services

    Choose a service

    not found

    Vacancies
    not found

    Appeals statistics (IVR system)
    not found

    Appeal of individuals and legal entities

    News

    Follow the news of our company!

    View all
    not found

    Adding milk improves the effectiveness of oral drugs

    Good old reliable milk. New research found that when it's combined with particular oral drugs, milk significantly improves their absorption by the body. It’s the latest in a series of studies showing that milk is a highly effective drug-delivery vehicle. For something that many of us take for granted, milk has turned out to be incredibly valuable in the world of health and medicine. Over the years, New Atlas has reported on cows that produce human breast milk, HIV-inhibiting milk, or milk containing human insulin. But what’s become increasingly clear to scientists is that milk’s composition makes it an effective drug delivery system. A new Monash University-led study found that adding both human and cow’s milk significantly improved the effectiveness of certain oral drugs. It’s the latest in a series of studies in which the researchers have investigated milk as a vehicle for improving drug delivery. “Through our research over the years, we’ve consistently been able to demonstrate the way in which certain medicines are able to ‘piggyback’ with the milk, which our body treats like food and digests,” said Ben Boyd, a professor in the Monash Institute of Pharmaceutical Sciences (MIPS) and the study’s corresponding author. “Through this process, the milk and drug are absorbed, thereby enhancing the effectiveness of the drug.” The term ‘bioavailability’ refers to how much of a drug actually reaches the bloodstream. Oral bioavailability, the bioavailability of drugs that are swallowed or otherwise delivered into the stomach, is affected by several factors, including the pH of the stomach and small intestine and enzymes and metabolism in the gastrointestinal (GI) tract. Therefore, the key to maximizing bioavailability is a drug’s formulation, which affects how well it is absorbed, distributed, and utilized by the body. Many drugs are poorly water-soluble and lipophilic (fat-loving), and both pose challenges to bioavailability. As you’re probably aware, the human body, including the GI tract, is mostly water, so if a drug doesn’t dissolve well in water, its absorption into the bloodstream will be incomplete. Lipophilic drugs need fat for proper dissolution and absorption (which is why your pharmacist might tell you to take a particular medication with food).

    • 25 February, 09:00
    • Read more
    not found

    Argentina to withdraw from World Health Organization

    Argentina is pulling out of the World Health Organization (WHO).  President Javier Milei has ordered Foreign Minister Gerardo Werthein to withdraw the country from the organization, due to “deep differences” over how the WHO managed the COVID-19 pandemic, Presidential spokesman Manuel Adorni announced in a press conference on Wednesday morning.  The Milei administration’s announcement was made in lockstep with the United States’ withdrawal from the global public health agency, underscoring Argentina’s alignment with President Donald Trump. Adorni said that the WHO’s pandemic management, along with decisions made by former President Alberto Fernández, “led [Argentina] to the longest lockdown in human history” and for the country to be subject to “certain countries’ political influence.” “Argentines won’t allow for an international organization to intervene in our sovereignty, much less in our health,” Adorni said. The government has claimed that exiting the WHO will not affect healthcare in Argentina. However, critics were quick to argue that it would affect important components of the country’s public health system, including vaccine purchases and outbreak monitoring.

    • 7 February, 11:53
    • Read more
    not found

    41% of companies worldwide plan to reduce workforces by 2030 due to AI

    Artificial intelligence is coming for your job: 41% of employers intend to downsize their workforce as AI automates certain tasks, a World Economic Forum survey showed Wednesday. Out of hundreds of large companies surveyed around the world, 77% also said they were planning to reskill and upskill their existing workers between 2025-2030 to better work alongside AI, according to findings published in the WEF’s Future of Jobs Report. But, unlike the previous, 2023 edition, this year’s report did not say that most technologies, including AI, were expected to be “a net positive” for job numbers. “Advances in AI and renewable energy are reshaping the (labor) market — driving an increase in demand for many technology or specialist roles while driving a decline for others, such as graphic designers,” the WEF said in a press release ahead of its annual meeting in Davos later this month. Writing in the wide-ranging report, Saadia Zahidi, the forum’s managing director, highlighted the role of generative AI in reshaping industries and tasks across all sectors. The technology can create original text, images and other content in response to prompts from users. Related articleAI will shrink workforces within five years, say company execs Postal service clerks, executive secretaries and payroll clerks are among jobs that employers expect to experience the fastest decline in numbers in coming years, whether due to the spread of AI or other trends. “The presence of both graphic designers and legal secretaries just outside the top 10 fastest-declining job roles, a first-time prediction not seen in previous editions of the Future of Jobs Report, may illustrate GenAI’s increasing capacity to perform knowledge work,” the report said. Conversely, AI skills are increasingly in demand. Close to 70% of companies are planning to hire new workers with skills to design AI tools and enhancements, and 62% intend to recruit more people with skills to better work alongside AI, according to the latest survey, conducted last year. Striking an optimistic note, the report said the primary impact of technologies such as generative AI on jobs might lie in their potential for “augmenting” human skills through “human-machine collaboration,” rather than in outright replacement, “particularly given the continued importance of human-centered skills.” However, many workers have already been replaced by AI. In recent years, some tech firms, including file storage service Dropbox and language-learning app Duolingo, have cited AI as a reason for making layoffs.

    • 14 January, 09:05
    • Read more
    not found

    WHO: About half of the world's population suffers from oral diseases

    Most oral health conditions are largely preventable and can be treated in their early stages. Most cases are dental caries (tooth decay), periodontal diseases, tooth loss and oral cancers. Other oral conditions of public health importance are orofacial clefts, noma (severe gangrenous disease starting in the mouth mostly affecting children) and oro-dental trauma. The WHO Global Oral Health Status Report  estimated that oral diseases affect close to 3.5 billion people worldwide, with 3 out of 4 people affected living in middle-income countries. Globally, an estimated 2 billion people suffer from caries of permanent teeth and 514 million children suffer from caries of primary teeth.   Prevalence of the main oral diseases continues to increase globally with growing urbanization and changes in living conditions. This is primarily due to inadequate exposure to fluoride (in the water supply and oral hygiene products such as toothpaste), availability and affordability of food with high sugar content and poor access to oral health care services in the community. Marketing of food and beverages high in sugar, as well as tobacco and alcohol, have led to a growing consumption of products that contribute to oral health conditions and other NCDs. Periodontal (gum) disease Periodontal disease affects the tissues that both surround and support the teeth. The disease is characterized by bleeding or swollen gums (gingivitis), pain and sometimes bad breath. In its more severe form, the gum can come away from the tooth and supporting bone, causing teeth to become loose and sometimes fall out. Severe periodontal diseases are estimated to affect around 19% of the global adult population, representing more than 1 billion cases worldwide. The main risk factors for periodontal disease are poor oral hygiene and tobacco use. Edentulism (total tooth loss) Losing teeth is generally the end point of a lifelong history of oral disease, mainly advanced dental caries and severe periodontal disease, but can also be due to trauma and other causes. The estimated global average prevalence of complete tooth loss is almost 7% among people aged 20 years or older. For people aged 60 years or older, a much higher global prevalence of 23% has been estimated. Losing teeth can be psychologically traumatic, socially damaging and functionally limiting. Oral cancer Oral cancer includes cancers of the lip, other parts of the mouth and the oropharynx and combined rank as the 13th most common cancer worldwide. The global incidence of cancers of the lip and oral cavity is estimated to be 377 713 new cases and 177 757 deaths in 2020. Oral cancer is more common in men and in older people, more deadly in men compared to women and it varies strongly by socio-economic circumstances. Tobacco, alcohol and areca nut (betel quid) use are among the leading causes of oral cancer. In North America and Europe, human papillomavirus infections are responsible for a growing percentage of oral cancers among young people. Oro-dental trauma Oro-dental trauma results from injury to the teeth, mouth and oral cavity. Latest estimates show that 1 billion people are affected, with a prevalence of around 20% for children up to 12 years old. Oro-dental trauma can be caused by oral factors such as lack of alignment of teeth and environmental factors (such as unsafe playgrounds, risk-taking behaviour, road accidents and violence). Treatment is costly and lengthy and sometimes can even lead to tooth loss, resulting in complications for facial and psychological development and quality of life. Risk factors Most oral diseases and conditions share modifiable risk factors such as tobacco use, alcohol consumption and an unhealthy diet high in free sugars that are common to the 4 leading NCDs (cardiovascular disease, cancer, chronic respiratory disease and diabetes). "Oral health is an important part of well-being, yet millions of people lack access to the services they need to protect and promote their oral health,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. That is why WHO is calling on governments to develop measures to improve access to prevention, diagnosis and treatment of oral diseases. In particular, the first ever global meeting on oral health, organized by WHO, is expected to approve a joint declaration adopted by delegations from more than 110 countries. This declaration aims to achieve oral health goals by 2030. Prevention The burden of oral diseases and other noncommunicable diseases can be reduced through public health interventions by addressing common risk factors. These include: promoting a well-balanced diet low in free sugars and high in fruit and vegetables, and favouring water as the main drink; stopping use of all forms of tobacco, including chewing of areca nuts; reducing alcohol consumption; and encouraging use of protective equipment when doing sports and travelling on bicycles and motorcycles (to reduce the risk of facial injuries). Adequate exposure to fluoride is an essential factor in the prevention of dental caries. Twice-daily tooth brushing with fluoride-containing toothpaste (1000 to 1500 ppm) should be encouraged.

    • 29 November, 12:00
    • Read more
    not found

    OIVdan o'lim va kasallanishning global pasayishi: Lancet sharhi

    Between 2010 and 2021, global statistics on HIV morbidity and mortality showed significant improvements. According to an article in The Lancet, the number of new infections decreased by nearly 22%, and deaths related to HIV dropped by 40%. The research, conducted across 204 countries and regions, revealed key trends in HIV morbidity and mortality. By 2021, the number of people living with HIV had reached 40 mln, an increase of 10.5 mln from 29.5 mln in 2010. In 2010, there were 2.11 mln new infections and 1.19 mln deaths. By 2021, these figures had declined to 1.65 mln new infections and 718,000 deaths. The most notable improvements were observed in sub-Saharan Africa and South Asia. In these regions, the risk of HIV infection decreased from 21.8% to 8.7% despite still being considered high by current standards. Additionally, the number of deaths in these areas fell from 106.5 to 45.5 per 100,000 people. Conversely, the situation worsened in Central and Eastern Europe and Central Asia, where the number of HIV-related deaths rose by 10.4%. Forecasts by scientists indicate a continued decline in HIV morbidity and mortality. It is anticipated that 513,000 people will die from HIV by 2030, with the number expected to decrease to 327,000 by 2050. Meanwhile, the number of individuals living with HIV is projected to grow, reaching 43.7 mln by 2030 and 44.4 mln by 2039, before gradually declining.

    • 28 November, 09:00
    • Read more
    not found

    Proposals on healthcare reviewed

    On November 14, President Shavkat Mirziyoyev got acquainted with a presentation of proposals on early detection and effective treatment of diseases. In Uzbekistan’s social policy, much attention is paid to healthcare. Over the past seven years, the amount of funds allocated to this area has increased sixfold. More than 400 high-tech operations, which were previously carried out only in Tashkent, are now performed in the regions and districts. To detect diseases early, oncology, endocrinology, and cardiology centers conduct screening examinations in the regions. For example, 1 million 700 thousand women were screened, and 49 thousand were diagnosed with precancerous diseases. In the first half of this year, 122 thousand people were diagnosed with cardiovascular diseases and diabetes at an early stage. Popular health protection is a continuous process. Based on the analysis and needs in the area, proposals have been prepared in essential areas. This was discussed at the presentation. One of the main problems in treatment is the late detection of the disease. Therefore, at the initiative of the President of Uzbekistan, a bonus of 2 million UZS for each case of early detection of oncological diseases was introduced in Kashkadarya as an experiment. As a result, family doctors identified such signs in 51 women and children in the assigned mahallas. 102 million UZS in bonuses were allocated for this, which saved 8 billion UZS that would have been required for treatment if the disease had been detected late. According to the analysis, on average, 20-25 percent of all oncological diseases are breast and uterine cancer. In this regard, it is planned to expand screenings and maintain a registry. Also, this year, three-year programs for the early detection and treatment of hematological, cardiological, and endocrinological diseases will be completed. Responsible persons have been instructed to analyze the achieved results and consider the possibility of extending these programs. The centralized procurement of medicines for medical institutions has shortcomings. Some hospitals have purchased fewer drugs than required, while others have an excess. In this regard, a system for purchasing medicines and medical devices based on fifteen-month demand is proposed. At the same time, the needs for subsequent years will be formed no later than August 1, simultaneously with the parameters of the State Budget. Also, a Procurement Center and its 13 regional branches will be created under the Ministry of Health. From January 1, 2025, the center can purchase original medicines and consumables for closed-type laboratory equipment directly from manufacturers. Another proposal expands donor support. In particular, the one-time cash reward for holders of the “Honorary Donor of the Republic of Uzbekistan” badge is increased from 5 to 15 basic calculation units. They will also be granted the right to free use of public transport and out-of-turn treatment in state sanatoriums. The introduction of the new system is scheduled for January 1 next year. The issue of introducing a procedure for informing the World Trade Organization about sanitary and phytosanitary measures applied in the country was also considered.

    • 15 November, 09:00
    • Read more
    not found

    US FDA approves AstraZeneca's self-administered nasal spray flu vaccine

    The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for self-administration, making it the first of its kind. FluMist is the first vaccine to prevent influenza that does not need to be administered by a healthcare provider, the regulator said. The flu is a common and contagious respiratory disease caused by influenza viruses that typically circulates in the U.S. during the fall and winter. AstraZeneca plans to make the vaccine available through a third-party online pharmacy. Customers will have to complete a screening and eligibility assessment when they order FluMist. The approval provides a new option for receiving a safe and effective seasonal influenza vaccine potentially with greater convenience, flexibility and accessibility for individuals and families, said Peter Marks, director of the FDA's Center for Biologics Evaluation and Research. The vaccine, which was first approved in 2003 to be administered only by healthcare providers, contains a weakened form of live influenza virus strains and is sprayed in the nose. According to the U.S. Centers for Disease Control and Prevention, the flu has resulted in approximately 9.3 million to 41 million illnesses, 100,000 to 710,000 hospitalizations, and 4,900 to 51,000 deaths annually between 2010 and 2023. The FDA said individuals between two and 17 years old should not self-administer FluMist, they should get it from a caregiver instead.

    • 23 September, 09:45
    • Read more
    not found

    New global guidance aims to curb antibiotic pollution from manufacturing

    The World Health Organization (WHO) has published its first-ever guidance on antibiotic pollution from manufacturing. The new guidance on wastewater and solid waste management for antibiotic manufacturing sheds light on this important but neglected challenge ahead of the United Nations General Assembly (UNGA) High-Level Meeting on antimicrobial resistance (AMR) taking place on 26 September 2024. The emergence and spread of AMR caused by antibiotic pollution could undermine the effectiveness of antibiotics globally, including the medicines produced at the manufacturing sites responsible for the pollution. Despite high antibiotic pollution levels being widely documented, the issue is largely unregulated and quality assurance criteria typically do not address environmental emissions. In addition, once distributed, there is a lack of information provided to consumers on how to dispose of antibiotics when they are not used, for example, when they expire or when a course is finished but there is still antibiotic left over. “Pharmaceutical waste from antibiotic manufacturing can facilitate the emergence of new drug-resistant bacteria, which can spread globally and threaten our health. Controlling pollution from antibiotic production contributes to keeping these life-saving medicines effective for everyone," said Dr Yukiko Nakatani, WHO Assistant Director-General for AMR ad interim. Globally, there is a lack of accessible information on the environmental damage caused by manufacturing of medicines. “The guidance provides an independent and impartial scientific basis for regulators, procurers, inspectors, and industry themselves to include robust antibiotic pollution control in their standards,” said Dr Maria Neira, Director, Department of Environment, Climate Change and Health, WHO. “Critically, the strong focus on transparency will equip buyers, investors and the general public to make decisions that account for manufacturers’ efforts to control antibiotic pollution.”  A range of international bodies have called for this guidance, including the WHO Executive Board, the G7 health ministers and UNEP. “The role of the environment in the development, transmission and spread of antimicrobial resistance needs careful consideration since evidence is mounting. There is a widespread agreement that action on the environment must become more prominent as a solution. This includes pollution prevention and control from municipal systems, manufacturing sites, healthcare facilities and agri-food systems,” said Jacqueline Alvarez, Chief of Branch for the Industry and Economy Division at the United Nations Environment Programme (UNEP). The guidance was developed in close collaboration with a diverse group of international experts representing academia, regulators, inspectors, international organizations such as UNEP, and other sectors. The draft also underwent public consultation, receiving valuable input from industry and other stakeholders. Industry has also taken up this challenge, though a voluntary industry-led initiative which can be updated in some areas to align with the new guidance.  The guidance provides human health-based targets to reduce the risk of emergence and spread of AMR, as well as targets to address risks for aquatic life caused by all antibiotics intended for human, animal or plant use. It covers all steps from the manufacturing of active pharmaceutical ingredients (APIs) and formulation into finished products, including primary packaging. AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to medicines, making people sicker and increasing the risk of spread of infections that are difficult to treat, illness and deaths. AMR is driven largely by the misuse and overuse of antimicrobials, yet, at the same time, many people around the world do not have access to essential antimicrobial medicines.  

    • 6 September, 09:00
    • Read more
    not found

    Global cancer cases to rise by more than 75% by 2050, WHO predicts

    Global cancer cases are predicted to rise by more than 75% by 2050, according to the World Health Organization. Latest figures from the WHO’s cancer arm, the International Agency for Research on Cancer, makes plain the growing burden of cancer, rising from 14.1 million new cases and 8.2 million deaths worldwide in 2012 to 20 million new cases and 9.7 million deaths a decade later. The IARC predicts there will be more than 35 million new cancer cases by 2050, an increase of 77% from 2022 levels, and that deaths will have nearly doubled since 2012 to more than 18 million. The IARC said tobacco use, alcohol consumption and obesity were key factors behind the increasing incidence of cancer, as well as population ageing and growth. It predicts that the highest-income countries will record an additional 4.8 million new cases in 2050, but lower-income countries will experience the biggest proportional increases in cases. Cancer mortality in the latter countries is projected to almost double. Lung cancer is the most commonly diagnosed cancer worldwide, accounting for 12.4% of new cases and 18.7% of deaths. Female breast cancer is the second most common form, but while it accounts for 11.6% of cases, it causes fewer than 7% of deaths. Other major causes of death include bowel liver and stomach cancer.

    • 4 September, 15:00
    • Read more
    not found

    Calculate your personal long COVID risk

    The University of Queensland-led and developed COVID-19 Risk Calculator has been updated to determine a person's risk of developing long COVID. Developed in conjunction with scientists, clinicians and researchers from Flinders University, QUT, the University of Sydney and the Immunisation Coalition, the online calculator provides a personalized risk assessment of developing long COVID 6 months after infection. Associate Professor Kirsty Short from UQ's School of Chemistry and Molecular Biosciences said the tool will be useful in helping tackle the obstinate disease. "At least 65 million people globally are thought to suffer from the post-acute sequelae of COVID-19 (PASC), more commonly known as long COVID," Dr. Short said. "It's an incredibly debilitating disease causing more than 200 symptoms across 10 different organ systems and can affect individuals quite differently. Common symptoms include fatigue, brain fog and shortness of breath." Dr. Short said while diagnosing and treating long COVID is still in its infancy, there is now a strong understanding of the risk factors associated with the condition's development. "The calculator takes into account a range of personal factors including age, sex, comorbidities, vaccination status, number of previous infections and use of antiviral medications," she said. "All of this data allows our research-backed algorithm to provide a personalized risk assessment of developing long COVID. Users see their risk results either as 'a chance' or 'per million people'. The interface is user-friendly and easy to navigate for people of all ages and technological proficiencies." Associate Professor John Litt from Flinders University, a co-lead on the calculator project, said by helping to identify those who might be at higher risk, the tool allows for proactive measures and early interventions to potentially mitigate the severity and duration of long COVID symptoms. "While many adults don't see COVID-19 as a big issue now, many are concerned about getting long COVID," he said. "The chance of suffering long COVID increases with every bout of COVID-19 a person catches." Dr. Short said the project also puts a spotlight on the controllable factors that can lead to long COVID. "Incomplete vaccination, missed drug treatment during acute infection and repeat infections are the greatest controllable influencers that increase risk, so there are actions you can take right now to reduce that," she said. "Health managers and individuals in conjunction with clinicians can use the risk assessment tool for shared decision making on vaccination, infection-avoidant behaviors and pursuing early treatment during acute infection. "Knowing your personal risk and the steps you can take to protect your health can help us win the war against long COVID."

    • 6 August, 15:02
    • Read more

    Gallery

    View all
    not found
    20.10.2022
    not found
    20.10.2022
    not found
    14.10.2022
    not found
    11.09.2022
    not found
    30.08.2022
    not found
    06.08.2022
    not found
    06.08.2022
    not found
    06.08.2022
    not found
    12.07.2022

    Videagallery

    View all
    not found

    25 March, 15:32
    not found

    5 December, 09:05
    not found

    14 November, 09:05
    not found

    13 May, 12:17
    not found

    23 April, 12:05
    not found

    18 April, 14:25
    not found

    15 April, 12:08
    not found

    2 April, 14:56
    not found

    1 March, 11:23
    not found

    15 January, 12:00
    Stop corruption!

    Hotline

    (+99871) 120-16-61

    Interactive map

    Services

    not found

    ООО «INTEGRA DD»

    In 2010 in Samarkand, in order to implement a project to organize the production of injectable drugs in accordance with international standards of GMP, the company “InegtraDD” LLC was established. The total area of the plant with developed infrastructure is 11,200.0 sq.m.

    Go to website
    not found

    ООО «Dori-Darmon HCP»

    In 2007 “Dori Darmon HCP” LLC was established, represented in Uzbekistan under the brand name “Elysee Parfumerie”. The main activity is the retail sale of luxury cosmetics and perfumes.

    Go to website
    not found

    ООО «DD General Insurance»

    In 2011, “DD General Insurance” JSC was founded, the main task of which is to provide reliable insurance protection of property interests of legal entities and individuals. Today the company has its own solid customer base of numerous types of voluntary insurance. At the end of 2021 rating agency “Standard and Sensitive Ratings” assigned to the company solvency and reliability rating according to the national scale “uzA++” (the highest) with the “Stable” outlook which means that the company has an outstanding ability to fulfill its obligations and claims of policy holders in time and in full. In the future it is planned to develop the direction of compulsory health insurance.

    Go to website
    not found

    ООО «Dori-Darmon Garant»

    In 2005 an order was signed on the establishment of “Dori-Darmon Garant” LLC, with a customs warehouse with a total area of 2000 square meters, which provides modern storage service for imported medicines and medical devices. In 2012, for the first time in Uzbekistan was implemented a large-scale project of the concept “Smart warehouse”, which uses automated storage and logistics systems.

    Go to website
    not found

    ООО «Дори-Дармон Инвест»

    In 2004, “Dori Darmon Invest” LLC was organized, specializing in research of the pharmaceutical market of Uzbekistan, providing services for the registration of medicines for manufacturers who do not have their offices in the country.

    Go to website

    Partners

    not found
    not found
    not found
    not found

    State resources

    not found

    E-Government Projects Management Center
    not found

    Open Data Portal of the Republic of Uzbekistan
    not found

    National database of legislation jf the Republic of Uzbekistan
    not found

    Виртуальная приёмная Президента Республики Узбекистан
    not found

    Правительственный портал Республики Узбекистан
    not found

    Action strategy on five priority areas of development of the Republic of Uzbekistan in 2017-2021

    Questions

    and answers

    You can contact us with numbers +998 71 228-06-96 and 1002

    344 raw materials and materials, medical products and packaging materials, imported for the purpose of drug preparation in the pharmacy, used for feeding laboratory animals, pre-clinical research and drug production (including drug preparation) that are not produced in the Republic of Uzbekistan, will be exempted from customs duties until January 1st 2025.

    Вы можете связаться с нами по телефону +998 71 228-06-96 или же по короткому номеру 1002

    First of all, it is recommended to use antiseptics to disinfect hands. Hydrogen peroxide and furacilin are mainly antibacterial agents. Since antiseptic agents contain 70 percent ethyl alcohol, they have the ability to destroy the shells of viruses.

    not found

    Have questions?
    Let us help!

    Нажмите на кнопку ниже, чтобы прослушать текст Powered by GSpeech